Trial Profile
Phase 2 Study to Assess the Safety and Efficiency of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Phase Chronic Myelogenous Leukemia Patients
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2018
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms SESPI
- 24 Feb 2016 New trial record